Innovative Aseptic Processing of Antibody-Drug Conjugates.

Watch SKAN AG's Richard Denk and Bausch+Ströbel‘s Thomas Buehler as they dive into the latest developments in Innovative Aseptic Processing of Antibody-drug Conjugates.

With four antibody-drug conjugates (ADC) approved by the U.S. Food and Drug Administration (FDA), the development and manufacturing of targeted ADC therapies has become a booming field. Due to the intrinsic complexity of these drug entities, development and manufacturing of antibody-drug conjugates remains very challenging. Strict containment is required to guarantee the protection and safety of both operators and products.

You have missed the webinar on "Innovative Aseptic Processing of Antibody-Drug Conjugates"? No problem – The recorded version is available for you. Click here for registration.
Referenten